Business

Pfizer will dominate $28 billion COVID-pill market in 2022, analysis shows

The US pharma giant, already pulling in huge profits from its COVID vaccine, is estimated to reap billions from sales of its experimental therapy, Paxlovid.

Brisbane Times – Business

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in:Business